Biogen Diranersen Phase 2 CELIA Data: Why a 26% Cognitive Slowing and 12x Forward P/E Signal a Re-Rating
Biogen (BIIB) trades at 12.5x forward earnings after diranersen’s Phase 2 tau data showed 26% cognitive slowing. Why the $230 base-case target signals upside.